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The acute respiratory distress syndrome (ARDS), a clinical complication of severe acute lung
injury (ALI) in humans, is a leading cause of morbidity and mortality in critically ill patients. ALI
is characterized by disruption of the lung alveolar–capillary membrane barrier and resultant
pulmonary edema associated with a proteinaceous alveolar exudate. Current specific treatment
strategies for ALI/ARDS are lacking. We hypothesized that mesenchymal stem cells (MSCs), with
or without transfection with the vasculoprotective gene angiopoietin 1 (ANGPT1) would have
beneficial effects in experimental ALI in mice.
Methods and Findings
Syngeneic MSCs with or without transfection with plasmid containing the human ANGPT1
gene (pANGPT1) were delivered through the right jugular vein of mice 30 min after
intratracheal instillation of lipopolysaccharide (LPS) to induce lung injury. Administration of
MSCs significantly reduced LPS-induced pulmonary inflammation, as reflected by reductions in
total cell and neutrophil counts in bronchoalveolar lavage (BAL) fluid (53%, 95% confidence
interval [CI] 7%–101%; and 60%, CI 4%–116%, respectively) as well as reducing levels of
proinflammatory cytokines in both BAL fluid and lung parenchymal homogenates.
Furthermore, administration of MSCs transfected with pANGPT1 resulted in nearly complete
reversal of LPS-induced increases in lung permeability as assessed by reductions in IgM and
albumin levels in BAL (96%, CI 6%–185%; and 74%, CI 23%–126%, respectively). Fluorescently
tagged MSCs were detected in the lung tissues by confocal microscopy and flow cytometry in
both naı ¨ve and LPS-injured animals up to 3 d.
Conclusions
Treatment with MSCs alone significantly reduced LPS-induced acute pulmonary inflamma-
tion in mice, while administration of pANGPT1-transfected MSCs resulted in a further
improvement in both alveolar inflammation and permeability. These results suggest a potential
role for cell-based ANGPT1 gene therapy to treat clinical ALI/ARDS.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
The acute respiratory distress syndrome (ARDS), a clin-
ically important complication of severe acute lung injury
(ALI) in humans, is a signiﬁcant cause of morbidity and
mortality in critically ill patients [1–4]. Infectious etiologies,
such as sepsis and pneumonia, are leading causes of ALI/
ARDS [1,2]. Histologically, ALI/ARDS in humans is charac-
terized by a severe acute inﬂammatory response in the lungs
and neutrophilic alveolitis [1]. Inﬂammatory stimuli from
microbial pathogens, such as endotoxin (lipopolysaccharide
[LPS]), are well recognized for their ability to induce
pulmonary inﬂammation, and experimental administration
of LPS, both systemically and intratracheally, has been used
to induce pulmonary inﬂammation in animal models of ALI
[5–9].
The physiological hallmark of ARDS is disruption of the
alveolar–capillary membrane barrier (i.e., pulmonary vascu-
lar leak), leading to development of noncardiogenic pulmo-
nary edema, in which a proteinaceous exudate ﬂoods the
alveolar spaces, impairs gas exchange, and precipitates
respiratory failure [1,10,11]. Both alveolar epithelial and
endothelial cell (EC) injury and/or death have been impli-
cated in the pathogenesis of ALI/ARDS [1]. However, despite
decades of research, few therapeutic strategies for clinical
ARDS have emerged, and current speciﬁc options for
treatment are limited [12–16]. ARDS continues to be an
important contributor to prolonged mechanical ventilation
in the intensive care unit, and ARDS-associated mortality
remains high at 30%–50% despite optimal supportive care
[1,13,14,16].
Marrow-derived stem or progenitor cells are being eval-
uated for the treatment of a number of diseases that currently
have limited or no treatment options [17–22]. Recent studies
have demonstrated that bone marrow-derived mesenchymal
stem cells (MSCs) [23,24] can engraft in the injured lung
[25,26] and even differentiate into lung epithelial cells in vivo
[25,27,28]. MSCs may also exhibit immunosuppressive prop-
erties and have been suggested to be ‘‘immune-privileged’’,
and thus are protected from rejection, potentially permitting
their use in allotransplantation [29–34]. Therefore, MSCs may
have beneﬁcial effects in their own right in the therapy of ALI
[35].
Human angiopoeitin 1 (ANGPT1), a ligand for the
endothelial-restricted receptor TEK tyrosine kinase (TEK;
previously called TIE2) [36,37], plays an essential role in blood
vessel maturation and stabilization during embryonic devel-
opment. In the postnatal state, ANGPT1 maintains the
normal quiescent phenotype of vascular ECs, protecting
against vascular inﬂammation [38,39], reducing permeability
[40–42], and promoting EC survival [43–46]. Given its anti-
inﬂammatory, antipermeability, and endothelial-protective
characteristics, we hypothesized that ANGPT1 gene transfer
may be beneﬁcial in the treatment of ALI.
The combination of cell and gene therapies has proven
successful in the treatment of experimental pulmonary
hypertension [47–51]. This dual strategy not only allows
direct targeting of the lung for clinical intervention, but also
provides a site-speciﬁc source to release therapeutic proteins
and/or other cellular products of interest by the retained
cells. Therefore, the aim of this study was to evaluate the
effect of MSCs alone or in combination with the vasculopro-
tective factor ANGPT1 on lung inﬂammation and injury
induced by LPS in a murine model of ALI.
Materials and Methods
Characterization, Culture, and Transfection of MSCs
A frozen vial of murine MSCs (isolated from male C57Bl/6J
mice; courtesy of Tulane Center for Gene Therapy, New
Orleans, Louisiana, United States) was thawed and expanded
as previously described [52]. Differentiation of MSCs was
evaluated using a Mesenchymal Stem Cell Functional Identi-
ﬁcation Kit (R&D Systems, http://www.rndsystems.com/).
Chondrogenic and osteogenic differentiation assays were
performed in six-well Primaria plates (BD Biosciences, http://
www.bdbiosciences.com/). The adipogenic assay was per-
formed in eight-well Lab-Tek II Chamber Slide System
(NUNC, http://www.nuncbrand.com/). MSCs were labeled with
anti-mouse antibodies Sca-1 (clone E13–161.7), CD31 (clone
MEC13.3), CD34 (clone RAM34), VCAM-1 (clone 429[MVCA-
M.A]), Flk1 (clone Avas 12a1), cKit (clone 2B8), CD45R (clone
RA3-6B2), and CD11b (clone M1/70) and corresponding
isotype controls purchased from BD Biosciences, and analyzed
by ﬂow cytometer (Cytomics FC500, Beckman Coulter, http://
www.beckmancoulter.com/). MSCs used in all in vivo experi-
ments were between passages 8 and 11. The full-length coding
sequence of ANGPT1 (1115 bp) was cloned into the expression
vector pFLAG-CMV-1 (Sigma, http://www.sigmaaldrich.com/)
as previously described [51]. MSCs were transfected by
nuclear-targeting electroporation (nucleofection, Amaxa,
http://www.amaxa.com/), SuperFect (activated dendrimer,
Qiagen, http://www.qiagen.com/) or Lipofectamine (cationic
lipids, Invitrogen, http://www.invitrogen.com/). For the in vivo
study, nuclear-targeting electroporation was used to transfect
MSCs with ANGPT1 plasmid or empty vector plasmid. Human
ANGPT1 protein expression was veriﬁed by ELISA (R&D
Systems).
Murine Model of LPS-Induced ALI
All animal procedures were approved in advance by the
Animal Care Committee of St. Michael’s Hospital (Toronto,
Ontario, Canada). Carboxy-ﬂuorescein diacetate, succinimid-
yl ester (Vybrant CFDA SE Cell Tracer Kit, Invitrogen) was
used to label cells before injection into the animals. Aliquots
of MSCs were analyzed by ﬂow cytometry to conﬁrm
complete labeling. Female mice (19.9 6 1.3 g) were
anaesthetized and orally intubated with a sterile plastic
catheter, and challenged with intratracheal instillation of
800 lg of LPS (E. coli 055:B5; Sigma) dissolved in 50 llo f
normal saline. Saline, MSCs, MSCs transfected with pFLAG
(MSCs-pFLAG), or MSCs transfected by plasmid containing
human ANGPT1 (MSCs-pANGPT1) (2.5 3 10
5 cells, 100 ll
total volume) were slowly infused via a jugular venous canula
30 min following LPS challenge. Human ANGPT1 protein
expression was conﬁrmed by ELISA for each batch of MSCs-
pANGPT1 employed. Naı ¨ve mice (without LPS instillation)
were injected with saline or MSCs to serve as controls for any
inﬂammatory response that might result from the injected
MSCs. After infusion, the canula was withdrawn, the vein
ligated, and the incision sutured using silk suture. Mice were
humanely killed at 15 min or 3 d after MSC treatment to
collect tissues for analysis.
Due to the small size of the animals, two measurement
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MSCs-ANGPT1 Treatment of ALI Micegroups were required to collect all tissue samples required. In
one set of animals (n¼5 per group), lungs were lavaged three
times with 1 ml of saline. Total cell counts were determined
using a haemocytometer. Differential cell counts were deter-
mined on BAL smear slides that were stained with Hemacolor
(EMD Chemicals, http://www.emdbiosciences.com/). Number
of neutrophils was calculated as the percentage of neutrophils
multipliedbythetotalnumberofcellsintheBALﬂuidsample.
BAL ﬂuid collected was then centrifuged at 800 g,a n d
supernatant was collected for analysis of total protein,
albumin, IgM, and cytokine/chemokine levels. All analyses
wereperformedinablindedfashion.Theabdominalaortaand
vena cava were severed at the diaphragm, and the right
ventricleoftheheartperfusedwith10mlofheparinizedsaline.
The left lower lobe of the lung was snap-frozen, and later
processed for lung homogenates. The rest of the lung was
digested with dispase II (3.6 U/ml; Roche, http://www.roche.
com/) into a single-cell suspension, according to a previously
published protocol [53]. In another set of animals (n ¼ 5 per
group, except for the LPS/saline group [n ¼ 9] and the LPS/
MSCs group [n¼ 10]), blood was collected with a heparinized
needle through cardiac puncture, and later centrifuged at
2,000 g to obtain plasma sample. Lungs were divided into two
parts: the left lower lobe was collected as frozen tissue in OCT
(Optimal Cutting Temperature; SAKURA FINETEK, http://
www.sakura-americas.com/) and the rest was ﬁxed by 4%
paraformaldehyde for histology.
Histopathology
Lung tissues (two cross sections of right lower lobe and one
of right upper lobe) were ﬁxed in 4% paraformaldehyde,
embedded in parafﬁn, and cut into 5-lm thick sections.
Sections were stained with hematoxylin and eosin, and images
were taken with a Nikon Eclipse E800 microscope with a 403
objective. The average interalveolar septal thickness was
quantiﬁed in a blinded fashion by measuring the thickness of
all septae along a crosshair placed on each image (at least 150
septa per animal), using ImageJ software (National Institutes
of Health; http://rsb.info.nih.gov/). For the lung injury score,
images were evaluated by a investigator who was blinded to
the identity of the slides (WCL) following a previously
published scoring system [54].
Measurement of Albumin, IgM, Cytokines, and
Chemokines
Albumin and IgM levels in BAL ﬂuid samples were
measured using with a murine-speciﬁc albumin ELISA kit
(ALPCO Diagnostics, http://www.alpco.com/) and a murine-
speciﬁc IgM ELISA kit (Bethyl Laboratories, http://www.
bethyl.com/), respectively. Cytokine levels (IFN-c,T N F - a,
IL6, and IL1b) in BAL ﬂuid were measured with murine
cytokine-speciﬁc Quantikine ELISA kits (R&D Systems).
Chemokine levels in BAL ﬂuid, and cytokine/chemokine
levels in lung homogenates and plasma, were measured by
multiplex immunoassay (Luminex 100, Luminex, http://www.
luminexcorp.com/) using cytokine-speciﬁc bead kits (R&D
Systems). Lung homogenates were processed according to a
previously published protocol [55], and all results were
normalized (25 lg of total protein per sample) with individual
protein concentration measured from lung homogenate
samples by Bradford assay (Bio-Rad, http://www.bio-rad.com/).
MSCs Rentention Study
Mouse lung was digested into single cells using dispase II
enzyme (3.6 U/ml, Roche) according to a previously published
protocol [53]. The number of total cells recovered was
determined by using a hemocytometer. Isolated cells were
analyzed by a ﬂow cytometer (FC500, Beckman Coulter) with
a minimal collection of 30,000 events per sample. Cell nuclei
were counterstained with nuclear dye TO-PRO-3 (Invitro-
gen), and confocal microscopic images were collected with a
Leica TCS SL laser scanning confocal microscope.
Statistics
Data in ﬁgures are represented as individual data points in
a vertical dot plot, with a line to indicate the mean, except
data for surface marker expression on MSCs, and retention of
injected MSCs, in which data are represented as bar graphs
showing mean 6 standard error of the mean (SEM). Lung
injury score and septal thickness data are shown in tabular
form (mean 6 SEM). Differences between the treated groups
versus the injured group (LPS/saline) were assessed using a
one-way ANOVA (with post hoc comparisons using Dunnett
test) with statistic software (GraphPad Prism version 4.00;
http://www.graphpad.com/). A value of p , 0.05 was consid-
ered statistically signiﬁcant.
Results
Characterization and ANGPT1 Transfection of MSCs
Murine MSCs were demonstrated to differentiate into
three predominant mesenchymal lineages: adipocytes, osteo-
cytes, and chondrocytes (Figure 1A–1D). The cells were
uniformly positive for the stem cell surface marker Sca1 by
ﬂow cytometry (Figure 1E). Subpopulations of MSCs were
CD34
þand VCAM1
þ, as previously reported for murine MSCs
from the C57Bl/6J background [52]. The cells were negative
for both CD11b (monocyte marker) and CD45R (leukocyte
marker).
Flow cytometric analysis of MSCs transfected by nuclear-
targeting electroporation resulted in ;55% greater GFP
expression in live cells compared to transfection with either
SuperFect or Lipofectamine (unpublished data). At 24 h after
nucleofection with pANGPT1, ANGPT1 protein (724 6 283
pg/ml) was detected in the culture supernatant (from 5 3 10
5
cells), and levels were sustained for more than 5 d (Figure S1;
detailed methods described in Protocol S1). Phosphorylation
of the TEK receptor, mediated by human ANGPT1 protein
expressed using the same plasmid, has been previously
validated by our group [51]. Nontransfected or null-trans-
fected (empty vector) MSCs produced no detectable ANGPT1
protein.
Effect of MSCs Alone or Transfected with ANGPT1 on
Acute LPS-Induced Pulmonary Inflammation
LPS was administered to mice followed by an injection of
saline, MSCs alone, or MSCs transfected with pFLAG (null) or
ANGPT1 plasmid (MSCs-pANGPT1) (Figure 1F). The total
inﬂammatory cell count in the BAL ﬂuid was increased
approximately 20-fold at day 3 following administration of
LPS, mainly attributable to an increase in neutrophils
(around 80% of total cells in LPS/saline group). Treatment
of animals with MSCs alone signiﬁcantly reduced the total cell
and neutrophil counts in BAL ﬂuid (Figure 2A and 2B, p ,
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MSCs-ANGPT1 Treatment of ALI Mice0.05 compared to LPS/saline group). Treatment with MSCs-
pANGPT1 further reduced the BAL ﬂuid cell count to a level
similar to control, naı ¨ve mice (p , 0.01 for total cells and
neutrophils counts compared to LPS/saline group). Substitu-
tion of skin ﬁbroblasts or unfractionated bone marrow cells
for MSCs did not prevent the observed LPS-induced increase
in BAL ﬂuid cell counts (unpublished data).
Histological assessment of lung sections 3 d after the
administration of LPS revealed evidence of marked inﬂam-
matory inﬁltrates, interalveolar septal thickening, and inter-
stitial edema (Figure 2C). MSCs alone reduced airspace
inﬂammation, which was more apparent in mice treated with
MSCs-pANGPT1. Morphometric analysis measuring interal-
veolar septal thickness showed a modest increase in the LPS
alone group, with a signiﬁcant reduction in animals receiving
MSCs (Table 1). Severity of lung injury was also scored using a
semiquantitative histopathology score system [54], which
evaluates lung injury in four categories: alveolar septae,
alveolar hemorrhage, intra-alveolar ﬁbrin, and intra-alveolar
inﬁltrates. Although treatment with MSCs or MSCs-
pANGPT1 tended to reduce lung injury scores (Table 1),
the observed differences did not reach statistical signiﬁcance.
To further evaluate the anti-inﬂammatory actions by MSCs
and MSCs-pANGPT1, levels of proinﬂammatory cytokines
and chemokines were measured in BAL ﬂuid collected from
animals. Proinﬂammatory cytokines (IFN-c, TNF-a, IL6, and
IL1b) were all elevated in BAL ﬂuid in response to LPS
challenge compared with naı ¨ve animals receiving saline
(Figure 3). Treatment with MSCs alone variably decreased
the levels of proinﬂammatory cytokines, while treatment with
Figure 1. Characterization of MSCs Isolated from C57Bl/6J Mice, and Experimental Design for In Vivo Study
(A) Undifferentiated MSCs (P8) were seeded in a T75 flask at a density of 100 cells/cm
2 and found to expand readily in a fashion that started from a
single cell to colony.
(B) Staining with oil red-O was used to detect MSCs that differentiated into adipocytes, identified by perinuclear red staining of fat globules.
(C) Staining with alizarian red was used to detect MSCs that differentiated into osteocytes.
(D) MSCs that differentiated into chondrocytes were stained with toluidine blue. Photomicrographs were obtained with a 103(A and C) or a 203(B and
D) objective using a Nikon Eclipse TS100 inverted microscope.
(E) Flow cytometry was performed for surface marker expression on cultured MSCs. All data are presented as mean 6 SEM.
(F) C57Bl/6J mice initially received LPS by intratracheal instillation, followed by intravenous injection 30 min later with saline, cultured MSCs, MSCs-
pFLAG, or MSCs-pANGPT1. Mice were then sacrificed 15 min and 3 d after to assess cell retention, or 3 d after to evaluate the therapeutic efficacy. A
photomicrograph of MSCs-pANGPT1 was obtained using a Nikon Eclipse TS100 inverted microscope with a 103 objective 1 d after transfection and
prior to injection into animals.
doi:10.1371/journal.pmed.0040269.g001
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MSCs-ANGPT1 Treatment of ALI MiceMSCs-pANGPT1 dramatically reduced cytokine levels to the
baseline values observed in naı ¨ve mice. LPS instillation also
increased the levels of Cxcl2, JE (the murine homolog of
human CCL2), and KC (the murine homolog of human IL8) in
BAL ﬂuid, whereas treatment with MSCs, and to a greater
extent MSCs-pANGPT1, attenuated these increases. Similarly,
LPS-induced cytokine and chemokine levels in whole lung
homogenates were signiﬁcantly reduced by treatment with
MSCs or MSCs-pANGPT1 (Figure 4), however, in this case
MSCs alone did not differ signiﬁcantly from MSCs-pANGPT1
in reducing proinﬂammatory cytokine and chemokine levels.
Discrepancies in BAL cytokine levels between animals that
received non- or null-transfected MSCs were occasionally
noted, likely reﬂecting biological variability, since mice
Figure 2. Therapeutic Potential of MSCs, Alone or Transfected with pANGPT1, on LPS-Induced Lung Inflammation in Mice
(A and B) Total cell (A) and neutrophil (B) counts were performed on BAL fluid to evaluate lung airspace inflammation. There was a 19-fold increase in
total inflammatory cells in BAL fluid collected 3 d after LPS, which was reduced by 53% in MSCs-treated mice (non-/null-transfected), and by 96% with
MSCs-pANGPT1. Group comparisons were analyzed by one-way ANOVA with Dunnett post hoc test. *p , 0.05 and **p , 0.01, compared between LPS/
saline versus each treated group (MSCs, MSCs-pFLAG, or MSCs-pANGPT1). n ¼ 5 per group.
(C) Histological evaluation of therapeutic potential of MSCs and MSCs-pANGPT1 on LPS-induced lung injury in mice. Representative images of
hematoxylin and eosin stained lung sections from six experimental groups. Lungs were fixed with 4% paraformaldehyde, embedded in paraffin, and
then cut into 5-lm thick sections before being stained. Photomicrographs were obtained with a Nikon Eclipse E800 microscope with a 403objective.
Scale bar ¼ 20 lm.
doi:10.1371/journal.pmed.0040269.g002
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MSCs-ANGPT1 Treatment of ALI Micereceiving null-transfected MSCs usually showed results
similar to those in mice that received nontransfected MSCs.
No detectable differences in cytokine and chemokine levels in
plasma were observed among different treatment groups 3 d
after treatment, suggesting that intratracheal LPS instillation
induced localized inﬂammation in the lungs, and did not
result in prolonged systemic inﬂammation in our model
(unpublished data).
Effect of MSCs and MSCs-pANGPT1 on LPS-Induced Lung
Permeability
Concentrations of total protein, albumin, and IgM were
assayed on collected BAL ﬂuid to evaluate the integrity of the
alveolar–capillary membrane barrier and assess pulmonary
vascular leakage as a marker for ALI. These parameters of
vascular leak were markedly increased (total protein, 3-fold;
albumin, 4-fold; and IgM, 25-fold) in BAL ﬂuid 3 d after LPS
instillation compared to naı ¨ve mice. Whereas treatment with
MSCs alone partially reduced total protein, albumin, and IgM
levels (Figure 5), treatment with MSCs-pANGPT1 restored
these lung injury indicators to levels not different from naı ¨ve
control mice (p , 0.01 for total proteins and albumin, and p
, 0.05 for IgM compared to LPS/saline group, respectively).
To assess apoptosis in LPS-induced ALI mice with or without
treatment, caspase 3 and 7 activities were measured in lung
homogenate samples. Activities of caspase 3 and 7 in mouse
lungs tended to be increased 3 d after animals received
intratracheal instillation of LPS, which was normalized only
in mice that received MSCs-pANGPT1 treatment (Figure S2;
detailed method described in Protocol S1).
Persistence of MSCs in Mice with or without LPS-Induced
ALI
Retention of MSCs in the lung after central venous
injection was veriﬁed by confocal microscopy and ﬂow
cytometry. MSCs labeled with the green ﬂuorescent cell
tracker CFDA SE [56] were observed in lung sections from
both naı ¨ve and LPS-challenged mice sacriﬁced at 15 min
(initial retention, Figure 6A). Although labeled cells could still
be detected 3 d after injection, they were far less abundant
(Figure 6C). No cell-speciﬁc green ﬂuorescence was observed
in sections from animals that did not receive CFDA SE-
labeled cells (unpublished ﬁgure). To conﬁrm that the green
ﬂuorescence observed was indeed from an intact cell, a z-
series using laser scanning confocal microscopy was per-
formed showing blue nuclear staining surrounded by green
ﬂuorescence by CFDA SE labeling (Figure 6B). The percent-
age of the injected MSCs retained in the lungs was quantiﬁed
by ﬂow cytometry following dispase lung digestion. An
average 47% of injected cells were found in the lungs shortly
after MSCs delivery in LPS-challenged mouse lungs compar-
ing to 38% in naı ¨ve mice, though the difference was not
statistically signiﬁcant. Regardless of lung injury, the majority
of MSCs were lost from the lung after 3 d, leaving less than
8% of cells remaining (Figure 6D).
Discussion
In the present study, we demonstrate in a murine model of
ALI that administration of MSCs to the pulmonary circu-
lation partially prevented LPS-induced lung inﬂammation,
whereas treatment with pANGPT1-transfected MSCs resulted
in further improvement in both alveolar inﬂammation and
permeability. These ﬁndings have potentially important
implications for the treatment of ARDS, a clinical syndrome
resulting from ALI, which represents an important thera-
peutic problem contributing to high morbidity and mortality
of critically ill patients.
Cell-based gene transfer can overcome some of the
limitations of direct gene therapy for pulmonary diseases
[57], achieving selective and durable transgene expression in
the lung [48–51,58]. Since stem and progenitor cells have also
been reported to restore function of damaged tissue in
various preclinical disease models [47,48], it follows that
combining stem cell therapy with gene therapy might provide
additive beneﬁts. Indeed, we have reported that endothelial
progenitor cells engineered to overexpress endothelial NO
synthase were signiﬁcantly more effective than endothelial
progenitor cells alone in a monocrotaline model of vascular
injury, producing near complete reversal of established
pulmonary hypertension [48].
The choice of the most appropriate therapeutic gene is a
critical determinant of the potential efﬁcacy of a gene
therapy strategy, and requires a detailed understanding of
the pathogenic mechanisms underlying the target disorder.
ARDS is a complex clinical syndrome that is initiated by
injury to the lung, often in the setting of pneumonia or sepsis.
Some of the early features of ARDS can be reproduced by
administration of bacterial endotoxin (LPS), which acts via
TLR4 (Toll-like receptor 4) to induce the expression of
inﬂammatory cytokines and chemokines and up-regulate
leukocyte adhesion molecules, resulting in EC activation [5–
9,59]. Recently, it has been observed that activation of ECs in
response to inﬂammatory cytokines is tightly regulated by
ANGPT1. ANGPT1, the principal agonist of TEK, is an EC
survival and vascular stabilization factor that maintains
endothelial permeability in the normal postnatal vasculature
[39–42]. In contrast, ANGPT2, which binds with equal afﬁnity,
Table 1. Lung Injury Score and Septal Thickness in Mice with LPS-Induced ALI
Measure Naı ¨ve/Saline Naı ¨ve/MSCs LPS/Saline LPS/MSCs LPS/MSCs-pFLAG LPS/MSCs-pANGPT1
Lung injury score 1.80 6 0.37 1.60 6 0.51 4.00 6 0.68
a 2.78 6 0.74 3.40 6 1.29 3.00 6 0.84
Septal thickness (lm) 1.51 6 0.06 1.83 6 0.11 2.45 6 0.16
b 1.59 6 0.16
c 2.06 6 0.35 1.78 6 0.26
Data are represented as mean 6 standard error of the mean. n ¼ 5 per group, except LPS/saline group (n ¼ 9) and LPS/MSCs (n ¼ 10).
ap ¼ 0.0553 compared between naı ¨ve/saline versus LPS/saline groups (nonparametric test, Mann-Whitney).
bp , 0.01 compared between naı ¨ve/saline versus LPS/saline groups.
cp , 0.01 compared between LPS/saline versus LPS/MSCs groups (group comparisons were analyzed by one-way ANOVA with Dunnett’s post hoc test).
doi:10.1371/journal.pmed.0040269.t001
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MSCs-ANGPT1 Treatment of ALI MiceFigure 3. Levels of Proinflammatory Cytokines and Chemokines in BAL Fluid
Levels of the proinflammatory cytokines IFN-c, TNF-a, IL6, and IL1b in BAL fluid were measured using ELISA. In addition, chemokine levels (Cxcl2, JE
[murine homolog of human CCL2], and KC [murine IL8 homolog]) in BAL fluid were measured by multiplex immunoassay. Group comparisons were
analyzed by one-way ANOVA with Dunnett post hoc test. *p , 0.05 and **p , 0.01, LPS/saline versus each treated group (MSCs, MSCs-pFLAG, or MSCs-
pANGPT1). n ¼ 5 per group.
doi:10.1371/journal.pmed.0040269.g003
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MSCs-ANGPT1 Treatment of ALI Micehas been described as a TEK antagonist, inhibiting receptor
activation in response to ANGPT1 [60]. Fiedler et al. showed
that ANGPT2 overexpression sensitized ECs to inﬂammatory
stimuli and potentiated the up-regulation of adhesion
molecules such as ICAM1 and VCAM1 in response to
suboptimal doses of TNF-a [61]. Circulating levels of
ANGPT2 were found to be elevated in the plasma of patients
suffering from sepsis, and the administration of ANGPT2 led
to disruption of endothelial barrier both in vitro and in a
mouse model in vivo [62]. Moreover, ANGPT2 expression was
recently observed to be increased in alveolar epithelial cells
in response to hyperoxia-induced ALI, whereas ANGPT1
expression was reduced [63].
Therefore, a therapeutic strategy to restore the balance
between ANGPT1 and ANGPT2 expression may be useful in
modulating endothelial activation and inﬂammation in
response to ALI. Systemic pretreatment with an adenoviral
construct containing ANGPT1 by Witzenbichler et al. was
reported to improve hemodynamics, reduce adhesion mole-
cule expression and prolong survival in mice with endotoxic
shock [64]. Similarly, we have shown that ﬁbroblasts trans-
fected with ANGPT1 were moderately effective in reducing
ALI in rats when given one day prior to LPS, attenuating
airspace inﬂammation by 60% and reducing expression of
endothelial-selective adhesion molecules [65]. However, in
these studies gene transfer was performed prior to lung
Figure 4. Levels of Proinflammatory Cytokines and Chemokines in Lung Homogenate
Cytokine (TNF-a and IL6) and chemokine (Cxcl2, JE [murine homolog of human CCL2], and KC [murine IL8 homolog]) levels in lung homogenates were
measured by multiplex immunoassay. Group comparisons were analyzed by one-way ANOVA with Dunnett post hoc test. *p , 0.05 and **p , 0.01,
LPS/saline versus each treated group (MSCs, MSCs-pFLAG, or MSCs-pANGPT1). n ¼ 5 per group.
doi:10.1371/journal.pmed.0040269.g004
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which are more relevant for clinical therapy, would have been
equally effective. Furthermore, the Witzenbichler study used
intraperitoneal administration of endotoxin and systemic
gene therapy [64], and it is not possible to differentiate local
actions of ANGPT1 on lung inﬂammation from its actions in
the peripheral circulation.
The observed therapeutic effect of MSCs alone in ALI was
not entirely unexpected, since previous reports have sug-
gested that MSCs can inhibit the activation of dendritic cells,
T lymphocytes, and natural killer cells, reducing the secretion
of inﬂammatory cytokines (i.e., TNF-a, IFN-c), increasing the
release of anti-inﬂammatory cytokines (i.e., IL10, IL4), and
inducing a tolerant phenotype [66,67]. The immunomodula-
tory effects of MSCs have been studied in a number of
inﬂammatory states such as graft-versus-host disease [68] and
autoimmune encephalomyelitis [69]. It has also been sug-
gested that the immunosuppressive activity of MSCs, together
with their lack of expression of class II major histocompat-
ibility complex antigens, may confer an ‘‘immune-privileged’’
state in the context of allogenic transplantation, which could
greatly simplify their therapeutic use. Indeed, in early clinical
trials, the use of cultured allogenic MSCs was shown to be well
tolerated, and did not induce a detectable immune response
when transplanted into an unrelated recipient [30,70].
In the present study, there was an additional effect of
ANGPT1 overexpressing MSCs compared with MSCs alone,
not only on the extravasation of plasma proteins and
inﬂammatory cells, but also on the levels of various
inﬂammatory cytokines and chemokines in the BAL ﬂuid.
Interestingly, this additive effect was not apparent when these
mediators were measured in whole-lung homogenates.
ANGPT1 acts on TEK receptors, which are largely restricted
to the endothelium. Thus, it is likely that ANGPT1 would have
a preferential effect on the vascular endothelium, reducing
inﬂammatory cell trafﬁcking and plasma protein exudation
into the alveolar space, and possibly inhibiting EC apoptosis
as well. In contrast, effects of LPS on the airway epithelium or
resident alveolar macrophages may not be directly modulated
by ANGPT1. However, it should be noted that MSCs alone
resulted in a near complete reduction of tissue cytokine
expression, with the exception of Cxcl2, which in fact was
further reduced in the group receiving with pANGPT1-
transfected MSCs. It is also of interest that near complete
normalization of protein and inﬂammatory cell exudation
into the alveolus after intratracheal LPS instillation was
achieved with MSCs-pANGPT1 delivered to the pulmonary
circulation, despite the fact that alveolar permeability is
determined by the functional integrity of both the alveolar
epithelium and the alveolar endothelium, which together
constitute the alveolar–capillary membrane barrier of the
lung [1]. It has been well documented that LPS-induced ALI is
associated with up-regulation of adhesion molecules on the
endothelial surface [71]. Leukocyte adhesion to the activated
endothelium is a critical determinant of the alveolar
inﬂammatory response, leading to transmigration of inﬂam-
matory cells into the airspace and possible exacerbation of
epithelial injury and increased pulmonary vascular leak [71].
Thus, the synergistic effect of ANGPT1 gene transfer may be
attributed to its ability to reduce EC activation and thus block
the ampliﬁcation of lung injury that is dependent on the
Figure 5. Effect of MSCs and MSCs-pANGPT1 on LPS-Induced ALI
Therapeutic efficacy was assessed by measurement of total protein,
albumin, and IgM (biomarkers of pulmonary vascular leakage resulting
from disruption of the alveolar–capillary membrane barrier) in BAL fluid.
(A) Total protein concentration was measured by Bradford assay (A);
albumin was measured using a mouse-specific albumin ELISA (B); and
IgM was measured using a mouse IgM ELISA kit (C). Group comparisons
were analyzed by one-way ANOVA with Dunnett post hoc test. *p , 0.05
and **p , 0.01, LPS/saline versus each treated group (MSCs, MSCs-
pFLAG, or MSCs-pANGPT1). n ¼ 5 per group.
doi:10.1371/journal.pmed.0040269.g005
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into the injured lung.
On a separate note, we were unable to detect a signiﬁcant
increase in human ANGPT1 proteins in the lung tissue, BAL
ﬂuid, or plasma (unpublished data) after injection of
pANGPT1-transfected MSCs. We believe that this is due to
the lack of speciﬁc antibodies to human ANGPT1 that can
reliably detect the human ANGPT1 transgene product above
the ‘‘noise’’ of the endogenous mouse proteins. In a separate
study in which mice were allowed to survive up to 2 wk, a 20%
mortality (up to 9 d) was observed in the LPS/saline group. No
animals died in either the LPS/MSCs group or the LPS/MSCs-
Figure 6. Retention of Injected MSCs in Mice With or Without LPS-Induced ALI
MSCs were labeled with the cell tracing dye CFDA SE (green) prior to injection. Nuclei were stained with TO-PRO-3 (blue). Scale bars in
photomicrographs ¼ 20 lm. White arrows indicate labeled MSCs.
(A) Labeled MSCs were observed in 5 lm, PFA-fixed lung sections from LPS-injured mice sacrificed at 15 min (initial retention). Image obtained with a
Leica laser scanning confocal microscope with a 203 objective.
(B) A three-dimensional lung section from an animal that received labeled MSCs. Lung was inflated, stored in OCT, and cut into 50 lm thick sections. Z-
series images (30 sections, total thickness of the tissue scanned¼17.71 lm) were collected with a 633oil objective and projected in different axes, as
shown. Red autofluorescence shows outline of the alveolus.
(C) pANGPT1-transfected MSCs labeled with the green fluorescent cell tracker CFDA SE were observed in lung section from LPS-injured mice killed at 3
d. Photomicrographs were taken in z-axis with a 203 objective, then images were stacked using Leica confocal software.
(D) Lung lobes (left upper and all right lobes) from each animal were enzyme-digested into single cells before MSCs were counted by flow cytometry. n
¼ 5 per group.
doi:10.1371/journal.pmed.0040269.g006
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the effect of MSCs and MSCs-pANGPT1 at earlier time points
(unpublished data). There was no difference in the total cell
counts in BAL ﬂuid in LPS-injured mice that received
treatment with either MSCs or MSCs-pANGPT1, compared
to the LPS/saline group (1 d after LPS injury). However, 2 d
after LPS injury and treatment, there was a signiﬁcant
decrease in the total cell count in BAL ﬂuid from mice that
received MSCs and MSCs-pANGPT1 compared to controls,
though the difference between those two groups was not
signiﬁcant. Preliminary data measuring the systemic level of
IL1b suggested that plasma IL1b level peaked in LPS-injured
mice (1 d after LPS) without treatment (LPS/saline mice),
while most mice that had received treatment (LPS/MSCs or
LPS/MSCs-pANGPT1) had lower or undetectable levels.
Plasma IL1b rapidly declined in LPS-injured mice 2 d after
injury. Mice that had received treatment (MSCs or MSCs-
pANGPT1) had lower or undetectable levels.
We also examined whether the observed therapeutic effects
depended on the retention of MSCs. A slightly higher
proportion of cells were retained in injured lungs 15 minutes
after LPS exposure; however, the difference between injured
versus uninjured lung was not signiﬁcant, and in both cases
the majority of cells were lost from the lung by 3 d. Our
results are in agreement with those of Beckett et al., who
reported no signiﬁcant improvement in lung engraftment of
bone marrow-derived cells following endotoxin- or NO2-
induced lung injury together with irradiation [72]. However,
other studies have reported greater cell persistence after
certain forms of injury [26,73–75]. Nonetheless, it is clear that
the beneﬁt seen in response to cell-based therapy in the LPS
injury model did not require a high level of long-term
persistence of transplanted MSCs. This observation is con-
sistent with a number of reports of bone marrow cell therapy
following myocardial infarction [76,77], which point to an
important role for paracrine actions of transplanted cells on
neovascularization and tissue healing. However, the precise
mechanism by which genetically engineered MSCs confer a
therapeutic beneﬁt in the model of ALI remains to be
determined.
Study Limitations
It is important to recognize certain limitations of this
study. First of all, the LPS-induced model of ALI cannot fully
reproduce the complexity of clinical ALI/ARDS in human
patients. Therefore, it will be necessary to reproduce these
ﬁndings in more clinically relevant models, such as in animal
models of sepsis and pneumonia. As well, cell therapy was
given only 30 min after lung injury, and it will be important
to deﬁne the therapeutic window of this intervention at later
time points. Moreover, percentages of the retained cells in
the lung after transplantation were fairly low, and future
studies need to address the question of whether higher levels
of MSCs incorporation would provide more therapeutic
beneﬁt in this and other models of ALI. A further limitation
relates to the use syngeneic cells for cell therapy in the
current study, which avoids the issue of host immune
response. However, given the growing literature that these
MSCs may be ‘‘immune-privileged,’’ it will be important in
future work to explore whether the use of allogenic MSCs will
have the same beneﬁcial effects in this ALI model. The
translation of these promising results into an effective new
therapy for ARDS in patients will require, at the very least,
that these limitations be addressed.
Conclusion
In conclusion, we have shown that bone marrow-derived
MSCs reduced the severity of ALI when administered into the
pulmonary circulation of the LPS-injured mouse lung,
possibly by virtue of their well-characterized immunomodu-
latory actions. However, this effect was greatly potentiated
when these cells were engineered to overexpress the
vasculoprotective factor ANGPT1, a speciﬁc inhibitor of
inﬂammation and permeability in ECs. Our data show, to our
knowledge for the ﬁrst time, the synergistic action of
combined cell and gene therapy for ALI, and may provide a
basis for the development of an innovative approach for the
prevention and treatment of ARDS, which continues to be a
major cause of morbidity and mortality in critically ill
patients.
Supporting Information
Figure S1. Establishment of Optimal Conditions for Transfection of
Murine MSCs
MSCs were transfected by nuclear-targeting electroporation with
pFLAG (null transfection control using high efﬁciency protocol, solid
bar) or pANGPT1 (high cell survival or high efﬁciency protocol; grey
or diagonal stripes bar, respectively). Supernatants were collected for
7 d and ANGPT1 proteins produced by nucleofected cells each day
was quantiﬁed using ELISA. All plotted values represent net ANGPT1
proteins produced, in which the amount of ANGPT1 determined
from a medium alone control was subtracted (239.74 pg/ml). All data
are presented as mean 6 SEM.
Found at doi:10.1371/journal.pmed.0040269.sg001 (219 KB TIF).
Figure S2. Caspase 3 and 7 Activity in Lung Homogenate
Caspase 3 and Caspase 7 activities in mouse lung homogenates were
measured by a commercially available kit. n ¼ 5 per group.
Found at doi:10.1371/journal.pmed.0040269.sg002 (70 KB TIF).
Protocol S1. Detailed Information on Transfection of Murine MSCs
and Measurement of Caspase-3/7 Activities in Lung Samples
Found at doi:10.1371/journal.pmed.0040269.sd001 (20 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/) accession numbers of the
genes discussed in this paper are ANGPT1 (GeneID 284); ANGPT2
(GeneID 285); TEK (GeneID 7010).
Acknowledgments
The authors would like to thank W. Slaid Jones, John T. Ruzinski, Judy
Trogadis, QiuWang Zhang, and Jack Haitsma for their technical
assistance; and Dr. David Courtman, Dr. Diego Alvarez, and Patrick
Lai for their helpful discussions. SHJM holds a NSERC Doctoral
Canada Graduate Scholarship. SDM is supported by the Heart &
Stroke Foundation of Canada/Pﬁzer Canada Fellowship Award and
the TACTICS Strategic Training Program in Cardiovascular Re-
search. CHP was supported by a University of Toronto Institute of
Medical Science Summer Student Scholarship. WCL is the recipient
of a Canada Research Chair (Tier I) in Infectious Diseases and
Inﬂammation.
Author contributions. SHJM, SDM and DJS designed the study.
SHJM, WCL, and DJS analyzed the data. SHJM, YD, CHP, WCL, and
DJS contributed to writing the paper. SHJM, SDM, and YD collected
data and performed in vivo experiments for this study. SHJM and
SDM established the model together, performed surgeries on mice in
tandem, and collected all tissues together. SDM also contributed to
some of the very preliminary data analysis. SHJM and CHP were
involved in culturing, profiling, labeling, and transfecting the MSCs,
and performed ELISAs as well as the confocal microscopy work.
PLoS Medicine | www.plosmedicine.org September 2007 | Volume 4 | Issue 9 | e269 1535
MSCs-ANGPT1 Treatment of ALI MiceReferences
1. Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. N
Engl J Med 342: 1334–1349.
2. Goss CH, Brower RG, Hudson LD, Rubenfeld GD (2003) Incidence of acute
lung injury in the United States. Crit Care Med 31: 1607–1611.
3. Mendez JL, Hubmayr RD (2005) New insights into the pathology of acute
respiratory failure. Curr Opin Crit Care 11: 29–36.
4. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, et al. (2005)
Incidence and outcomes of acute lung injury. N Engl J Med 353: 1685–1693.
5. Kitamura Y, Hashimoto S, Mizuta N, Kobayashi A, Kooguchi K, et al. (2001)
Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-
induced lung injury in mice. Am J Respir Crit Care Med 163: 762–769.
6. Matute-Bello G, Winn RK, Martin TR, Liles WC (2004) Sustained
lipopolysaccharide-induced lung inﬂammation in mice is attenuated by
functional deﬁciency of the Fas/Fas ligand system. Clin Diagn Lab Immunol
11: 358–361.
7. Rojas M, Woods CR, Mora AL, Xu J, Brigham KL (2005) Endotoxin-induced
lung injury in mice: Structural, functional, and biochemical responses. Am
J Physiol Lung Cell Mol Physiol 288: L333–341.
8. Altemeier WA, Matute-Bello G, Gharib SA, Glenny RW, Martin TR, et al.
(2005) Modulation of lipopolysaccharide-induced gene transcription and
promotion of lung injury by mechanical ventilation. J Immunol 175: 3369–
3376.
9. Gharib SA, Liles WC, Matute-Bello G, Glenny RW, Martin TR, et al. (2006)
Computational identiﬁcation of key biological modules and transcription
factors in acute lung injury. Am J Respir Crit Care Med 173: 653–658.
10. Ware LB, Matthay MA (2001) Alveolar ﬂuid clearance is impaired in the
majority of patients with acute lung injury and the acute respiratory
distress syndrome. Am J Respir Crit Care Med 163: 1376–1383.
11. Guidot DM, Folkesson HG, Jain L, Sznajder JI, Pittet JF, et al. (2006)
Integrating acute lung injury and regulation of alveolar ﬂuid clearance. Am
J Physiol Lung Cell Mol Physiol 291: L301–306.
12. Crimi E, Slutsky AS (2004) Inﬂammation and the acute respiratory distress
syndrome. Best Pract Res Clin Anaesthesiol 18: 477–492.
13. The Acute Respiratory Distress Syndrome Network (2000) Ventilation with
lower tidal volumes as compared with traditional tidal volumes for acute
lung injury and the acute respiratory distress syndrome. N Engl J Med 342:
1301–1308.
14. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, et al.
(2003) Future research directions in acute lung injury: Summary of a
National Heart, Lung, and Blood Institute working group. Am J Respir Crit
Care Med 167: 1027–1035.
15. Mehta D, Bhattacharya J, Matthay MA, Malik AB (2004) Integrated control
of lung ﬂuid balance. Am J Physiol Lung Cell Mol Physiol 287: L1081–1090.
16. Slutsky AS, Hudson LD (2006) PEEP or no PEEP—Lung recruitment may be
the solution. N Engl J Med 354: 1839–1841.
17. Koc ON, Lazarus HM (2001) Mesenchymal stem cells: Heading into the
clinic. Bone Marrow Transplant 27: 235–239.
18. Barry FP, Murphy JM (2004) Mesenchymal stem cells: Clinical applications
and biological characterization. Int J Biochem Cell Biol 36: 568–584.
19. Horwitz EM (2003) Stem cell plasticity: The growing potential of cellular
therapy. Arch Med Res 34: 600–606.
20. Dominici M, Hofmann TJ, Horwitz EM (2001) Bone marrow mesenchymal
cells: Biological properties and clinical applications. J Biol Regul Homeost
Agents 15: 28–37.
21. Baksh D, Song L, Tuan RS (2004) Adult mesenchymal stem cells:
Characterization, differentiation, and application in cell and gene therapy.
J Cell Mol Med 8: 301–316.
22. Stripp BR, Shapiro SD (2006) Stem cells in lung disease, repair, and the
potential for therapeutic interventions: State-of-the-art and future
challenges. Am J Respir Cell Mol Biol 34: 517–518.
23. Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic
tissues. Science 276: 71–74.
24. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al.
(2006) Minimal criteria for deﬁning multipotent mesenchymal stromal
cells. The International Society for Cellular Therapy position statement.
Cytotherapy 8: 315–317.
25. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, et al. (2003)
Mesenchymal stem cell engraftment in lung is enhanced in response to
bleomycin exposure and ameliorates its ﬁbrotic effects. Proc Natl Acad Sci
U S A 100: 8407–8411.
26. Yamada M, Kubo H, Kobayashi S, Ishizawa K, Numasaki M, et al. (2004)
Bone marrow-derived progenitor cells are important for lung repair after
lipopolysaccharide-induced lung injury. J Immunol 172: 1266–1272.
27. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, et al. (2001)
Bone marrow-derived cells as progenitors of lung alveolar epithelium.
Development 128: 5181–5188.
28. Grove JE, Lutzko C, Priller J, Henegariu O, Theise ND, et al. (2002) Marrow-
derived cells as vehicles for delivery of gene therapy to pulmonary
epithelium. Am J Respir Cell Mol Biol 27: 645–651.
29. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, et al. (2002) Allogeneic
mesenchymal stem cell infusion for treatment of metachromatic leukodys-
trophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant
30: 215–222.
30. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, et al. (2002) Isolated
allogeneic bone marrow-derived mesenchymal cells engraft and stimulate
growth in children with osteogenesis imperfecta: Implications for cell
therapy of bone. Proc Natl Acad Sci U S A 99: 8932–8937.
31. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, et al. (2006) Role for
interferon-gamma in the immunomodulatory activity of human bone
marrow mesenchymal stem cells. Stem Cells 24: 386–398.
32. Frank MH, Sayegh MH (2004) Immunomodulatory functions of mesen-
chymal stem cells. Lancet 363: 1411–1412.
33. Le Blanc K (2003) Immunomodulatory effects of fetal and adult
mesenchymal stem cells. Cytotherapy 5: 485–489.
34. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, et al. (2002)
Human bone marrow stromal cells suppress T-lymphocyte proliferation
induced by cellular or nonspeciﬁc mitogenic stimuli. Blood 99: 3838–3843.
35. Neuringer IP, Randell SH (2004) Stem cells and repair of lung injuries.
Respir Res 5: 6.
36. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, et al. (1996)
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-
trap expression cloning. Cell 87: 1161–1169.
37. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, et al. (1996)
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during
embryonic angiogenesis. Cell 87: 1171–1180.
38. Thurston G, Rudge JS, Ioffe E, Papadopoulos N, Daly C, et al. (2005) The
anti-inﬂammatory actions of angiopoietin-1. EXS 233–245.
39. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, et al. (2000)
Angiopoietin-1 is an antipermeability and anti-inﬂammatory agent in vitro
and targets cell junctions. Circ Res 87: 603–607.
40. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, et al. (2000) Angiopoietin-1
protects the adult vasculature against plasma leakage. Nat Med 6: 460–463.
41. Baffert F, Le T, Thurston G, McDonald DM (2006) Angiopoietin-1 decreases
plasma leakage by reducing number and size of endothelial gaps in venules.
Am J Physiol Heart Circ Physiol 290: H107–118.
42. Thurston G, Suri C, Smith K, McClain J, Sato TN, et al. (1999) Leakage-
resistant blood vessels in mice transgenically overexpressing angiopoietin-
1. Science 286: 2511–2514.
43. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY (1999) Angiopoietin-1 is an
apoptosis survival factor for endothelial cells. FEBS Lett 448: 249–253.
44. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC,
Yancopoulos GD, et al. (1999) Direct actions of angiopoietin-1 on human
endothelium: Evidence for network stabilization, cell survival, and
interaction with other angiogenic growth factors. Lab Invest 79: 213–223.
45. Chen JX, Chen Y, DeBusk L, Lin W, Lin PC (2004) Dual functional roles of
Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am J Physiol
Heart Circ Physiol 287: H187–195.
46. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor DS, et al.
(2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/
survivin pathway. J Biol Chem 275: 9102–9105.
47. Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, et al.
(2006) Implantation of mesenchymal stem cells overexpressing endothelial
nitric oxide synthase improves right ventricular impairments caused by
pulmonary hypertension. Circulation 114: I181–185.
48. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, et al. (2005)
Rescue of monocrotaline-induced pulmonary arterial hypertension using
bone marrow-derived endothelial-like progenitor cells: Efﬁcacy of com-
bined cell and eNOS gene therapy in established disease. Circ Res 96: 442–
450.
49. Campbell AI, Zhao Y, Sandhu R, Stewart DJ (2001) Cell-based gene transfer
of vascular endothelial growth factor attenuates monocrotaline-induced
pulmonary hypertension. Circulation 104: 2242–2248.
50. Kugathasan L, Dutly AE, Zhao YD, Deng Y, Robb MJ, et al. (2005) Role of
angiopoietin-1 in experimental and human pulmonary arterial hyper-
tension. Chest 128: 633S–642S.
51. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ (2003) Protective role of
angiopoietin-1 in experimental pulmonary hypertension. Circ Res 92: 984–
991.
52. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, et al. (2004) Adult
stem cells from bone marrow (MSCs) isolated from different strains of
inbred mice vary in surface epitopes, rates of proliferation, and differ-
entiation potential. Blood 103: 1662–1668.
53. Harris RG, Herzog EL, Bruscia EM, Grove JE, Van Arnam JS, et al. (2004)
Lack of a fusion requirement for development of bone marrow-derived
epithelia. Science 305: 90–93.
54. Matute-Bello G, Winn RK, Jonas M, Chi EY, Martin TR, et al. (2001) Fas
(CD95) induces alveolar epithelial cell apoptosis in vivo: Implications for
acute pulmonary inﬂammation. Am J Pathol 158: 153–161.
55. Dhanireddy S, Altemeier WA, Matute-Bello G, O’Mahony DS, Glenny RW,
et al. (2006) Mechanical ventilation induces inﬂammation, lung injury, and
extra-pulmonary organ dysfunction in experimental pneumonia. Lab
Invest 86: 790–799.
56. Dooner M, Cerny J, Colvin G, Demers D, Pimentel J, et al. (2004) Homing
and conversion of murine hematopoietic stem cells to lung. Blood Cells
Mol Dis 32: 47–51.
57. Weiss DJ (2002) Delivery of gene transfer vectors to lung: Obstacles and the
role of adjunct techniques for airway administration. Mol Ther 6: 148–152.
58. Campbell AI, Kuliszewski MA, Stewart DJ (1999) Cell-based gene transfer to
PLoS Medicine | www.plosmedicine.org September 2007 | Volume 4 | Issue 9 | e269 1536
MSCs-ANGPT1 Treatment of ALI Micethe pulmonary vasculature: Endothelial nitric oxide synthase overexpres-
sion inhibits monocrotaline-induced pulmonary hypertension. Am J Respir
Cell Mol Biol 21: 567–575.
59. Fan J, Frey RS, Malik AB (2003) TLR4 signaling induces TLR2 expression in
endothelial cells via neutrophil NADPH oxidase. J Clin Invest 112: 1234–
1243.
60. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997)
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
angiogenesis. Science 277: 55–60.
61. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, et al. (2006)
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial
role in the induction of inﬂammation. Nat Med 12: 235–239.
62. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, et al. (2006)
Excess circulating angiopoietin-2 may contribute to pulmonary vascular
leak in sepsis in humans. PLoS Med 3: e46. doi:10.1371/journal.pmed.
0030046
63. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, et al. (2006)
Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic
cell death. Nat Med 12: 1286–1293.
64. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C
(2005) Protective role of angiopoietin-1 in endotoxic shock. Circulation
111: 97–105.
65. McCarter SD, Mei SH, Lai PF, Zhang Q, Parker CH, et al. (2007) Cell-based
angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care
Med 175: 1014–1026.
66. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood 105: 1815–1822.
67. Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, et al. (2006)
Human mesenchymal stem cells induce T cell anergy and downregulate T
cell allo-responses via the TH2 pathway: Relevance to tissue engineering
human heart valves. Tissue Eng 12: 2263–2273.
68. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, et al.
(2004) Treatment of severe acute graft-versus-host disease with third party
haploidentical mesenchymal stem cells. Lancet 363: 1439–1441.
69. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005)
Mesenchymal stem cells ameliorate experimental autoimmune encephalo-
myelitis inducing T-cell anergy. Blood 106: 1755–1761.
70. Ryan JM, Barry FP, Murphy JM, Mahon BP (2005) Mesenchymal stem cells
avoid allogeneic rejection. J Inﬂamm (Lond) 2: 8.
71. Zimmerman GA, Albertine KH, Carveth HJ, Gill EA, Grissom CK, et al.
(1999) Endothelial activation in ARDS. Chest 116: 18S–24S.
72. Beckett T, Loi R, Prenovitz R, Poynter M, Goncz KK, et al. (2005) Acute lung
injury with endotoxin or NO2 does not enhance development of airway
epithelium from bone marrow. Mol Ther 12: 680–686.
73. Anjos-Afonso F, Siapati EK, Bonnet D (2004) In vivo contribution of
murine mesenchymal stem cells into multiple cell-types under minimal
damage conditions. J Cell Sci 117: 5655–5664.
74. Theise ND, Henegariu O, Grove J, Jagirdar J, Kao PN, et al. (2002) Radiation
pneumonitis in mice: A severe injury model for pneumocyte engraftment
from bone marrow. Exp Hematol 30: 1333–1338.
75. Herzog EL, Van Arnam J, Hu B, Krause DS (2006) Threshold of lung injury
required for the appearance of marrow-derived lung epithelia. Stem Cells
24: 1986–1992.
76. van Laake L, Hassink R, Doevendans P, Mummery C (2006) Heart repair
and stem cells. J Physiol 577 (Pt 2): 467–478.
77. Fukuda K, Yuasa S (2006) Stem cells as a source of regenerative
cardiomyocytes. Circ Res 98: 1002–1013.
Editors’ Summary
Background. Critically ill people who have had an injury to their lungs,
for example through pneumonia, trauma, or an immune response to
infection, may end up developing a serious complication in the lung
termed acute respiratory distress syndrome (ARDS). In ARDS, inflamma-
tion develops in the lung, and fluid builds up in the alveoli (the air sacs
resembling ‘‘bunches of grapes’’ at the ends of the network of tubes in
the lung). This buildup of fluid prevents oxygen from being carried
efficiently from air into the blood; the individual consequently
experiences problems breathing and can develop further serious
complications, which contribute significantly to the burden of illness
among people in intensive care units. The death rate among individuals
who do develop ARDS is very high, upward of 30%. Normally, individuals
with ARDS are given extra oxygen, and may need a machine to help
them breathe; treatments also focus on addressing the underlying
causes in each particular patient. However, currently there are very few
specific treatments that address ARDS itself.
Why Was This Study Done? The researchers here wanted to work
toward new treatment options for individuals with ARDS. One possible
approach involves cells known as mesenchymal stem cells (MSCs). These
cells are typically found in the bone marrow and have a property shared
by very few other cell types in the body; they are able to carry on
dividing and renewing themselves, and can eventually develop into
many other types of cell. The researchers already knew that MSCs could
become incorporated into injured lungs in mice and develop there into
the tissue layers lining the lung. Some interesting work had also been
done on a protein called angiopoeitin 1 (ANGPT1), which seemed to play
a role in protecting against inflammation in blood vessels. Therefore,
there was a strong rationale for carrying out experiments in mice to see if
MSCs engineered to produce the ANGPT1 protein might ‘‘rescue’’ lung
injury in mice. These experiments would be an initial step toward
developing possible new treatments for humans with ARDS.
What Did the Researchers Do and Find? The researchers used a mouse
model to mimic the human ARDS condition. This involved injecting the
windpipe of experimental mice with lipopolysaccharide (a substance
normally found on the outer surface of bacteria that brings about an
immune reaction in the lung). After 30 minutes, the mice were then
injected with either salt solution (as a control), the MSCs, or MSCs
producing the ANGPT1 protein. The researchers then looked at markers
of lung inflammation, the appearance of the lungs under a microscope,
and whether the injected MSCs had become incorporated into the lung
tissue.
The lipopolysaccharide brought about a large increase in the number of
inflammatory cells in the lung fluid, which was reduced in the mice given
MSCs. Furthermore, in mice given the MSCs producing ANGPT1 protein,
the number of inflammatory cells was reduced to a level similar to that of
mice that had not been given lipopolysaccharide. When the researchers
looked at the appearance under the microscope of lungs from mice that
had been given lipopolysaccharide, they saw signs of inflammation and
fluid coming out into the lung air spaces. These signs were reduced
among both mice treated with MSCs and those treated with MSCs
producing ANGPT1. The researchers also measured the ‘‘leakiness’’ of
the lung tissues in lipopolysaccharide-treated mice; MSCs seemed to
reduce the leakiness to some extent, and the lungs of mice treated with
MSCs producing ANGPT1 were no more leaky than those of mice that
had never been injected with lipopolysaccharide. Finally, the MSCs were
seen to be incorporated into lung tissue by three days after injection, but
after that were lost from the lung.
What Do These Findings Mean? Previous research done by the same
group had shown that fibroblasts producing ANGPT1 could prevent lung
injury in rats later given lipopolysaccharide. The experiments reported
here go a step further than this, and suggest that MSCs producing
ANGPT1 can ‘‘rescue’’ the condition of mouse lungs that had already
been given lipopolysaccharide. In addition, treatment with MSCs alone
also produced beneficial effects. This opens up a possible new treatment
strategy for ARDS in humans. However, it should be emphasized that the
animal model used here is not a precise parallel of ARDS in humans, and
that more research remains to be done before human studies of this sort
could be considered.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040269.
  Medline Plus entry on acute respiratory distress syndrome, providing
basic information about what ARDS is, its effects, and how it is
currently managed
  ARDS Network from the US National Heart, Lung, and Blood Institute
of the National Institutes of Health; the site provides frequently asked
questions about ARDS as well as a list of clinical trials conducted by
the network
  Information about stem cells from the US National Institutes of Health,
including information about the potential uses of stem cells
  Wikipedia page about mesenchymal stem cells (note: Wikipedia is an
internet encyclopedia anyone can edit)
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